Equities

Metagenomi Inc

MGX:NSQ

Metagenomi Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.57
  • Today's Change-0.06 / -2.28%
  • Shares traded192.38k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 19:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform5
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Metagenomi Inc have a median target of 17.00, with a high estimate of 25.00 and a low estimate of 7.00. The median estimate represents a 546.39% increase from the last price of 2.63.
High850.6%25.00
Med546.4%17.00
Low166.2%7.00

Earnings history & estimates in USD

On Aug 14, 2024, Metagenomi Inc reported 2nd quarter 2024 losses of -0.29 per share.
Average growth rate-27.94%
Metagenomi Inc reported annual 2023 losses of -20.05 per share on Mar 27, 2024.
More ▼

Revenue history & estimates in USD

Metagenomi Inc had 2nd quarter 2024 revenues of 20.01m. This bettered the 13.98m consensus of the 5 analysts covering the company. This was 61.37% above the prior year's 2nd quarter results.
Average growth rate+34.65%
Metagenomi Inc had revenues for the full year 2023 of 44.76m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.